Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Darren A. Gormley"'
Autor:
Lasse Stach, Emily K. H. Dinley, Nadia Tournier, Ryan P. Bingham, Darren A. Gormley, Jo L. Bramhall, Adam Taylor, Jane E. Clarkson, Katherine A. Welbeck, Claire L. Harris, Maria Feeney, Jane P. Hughes, Armin Sepp, Thil D. Batuwangala, Semra J. Kitchen, Eva-Maria Nichols
Publikováno v:
Antibodies, Vol 10, Iss 4, p 39 (2021)
The terminal pathway of complement is implicated in the pathology of multiple diseases and its inhibition is, therefore, an attractive therapeutic proposition. The practicalities of inhibiting this pathway, however, are challenging, as highlighted by
Externí odkaz:
https://doaj.org/article/9c08d3afb4f34afc913b99f6d81d4c48
Autor:
Jane E Clarkson, Nadia Tournier, Ryan P. Bingham, Maria Feeney, Semra Kitchen, Jo L Bramhall, Darren A. Gormley, Lasse Stach, Eva-Maria Nichols, Jane P. Hughes, Katherine A Welbeck, Claire L. Harris, Adam Taylor, Armin Sepp, Thil D. Batuwangala, Emily K H Dinley
Publikováno v:
Antibodies, Vol 10, Iss 39, p 39 (2021)
Antibodies
Volume 10
Issue 4
Antibodies
Volume 10
Issue 4
The terminal pathway of complement is implicated in the pathology of multiple diseases and its inhibition is, therefore, an attractive therapeutic proposition. The practicalities of inhibiting this pathway, however, are challenging, as highlighted by
Autor:
Natalie Buchan, Mark Spears, Amy Molesworth, Darren A. Gormley, Joyce Thompson, M Brannigan, Jane Lafferty, Euan J. Cameron, Rekha Chaudhuri, Stuart Farrow, Neil C. Thomson, Steven M. Fox
Publikováno v:
D32. HUMAN STUDIES OF IMMUNE DYSFUNCTION IN ASTHMA.
Autor:
Rabinder Kumar Prinjha, Allen D. Roses, Steven M. Fox, Nikos Tsokanas, John Yates, Marjorie A. Smith, Wen Wu, Israel S. Gloger, Jill C. Richardson, Wanda M. Bodnar, Joanna D. Holbrook, Paul Cutler, Christine Debouck, Emma L. Akuffo, A. Jacqueline Hunter, Emma E. Kinsey, Rachel A. Gibson, Darren A. Gormley, David R. Willé, Deborah M. Briggs, John B. Davis
Publikováno v:
Proteomics. Clinical applications. 2(4)
Emerging disease modifying therapeutic strategies for Alzheimer's disease (AD) have generated a critical need for biomarkers of early stage disease. Here, we describe the identification and assessment of a number of candidate biomarkers in patients w